Biochemical endocrinology of the hypogonadal male

Annals of Clinical Biochemistry

Volumn 47, Issue 6, 2010, Pages 503-515

  Belchetz, Paul E ^a   Barth, Julian H ^b   Kaufman, Jean Marc ^c  

^a Leeds Nuffield Hospital   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

AGING; HORMONAL THERAPY; HUMAN; HYPOGONADISM; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PUBERTY DISORDERS; REVIEW; SEXUALITY; SOMATIZATION; VIRILIZATION;

ADULT; ANDROGENS; ENDOCRINOLOGY; HUMANS; HYPOGONADISM; MALE; PUBERTY; TESTIS;

EID: 78449275536     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2010.010150     Document Type: Review

References (135)

1. Belchetz PE. Male hypogonadism. In: Grossman A, ed. Clinical Endocrinology. 2nd edn. Oxford: Blackwell Science, 1998:666-86
2. Jockenhövel F. Hypogonadism in men. In: Male Hypogonadism. Bremen: Uni-Med Verlag AG, 2004:30-7
3. Belchetz PE. Endocrine factors in male gonadal dysfunction. In: Hendry WF, ed. Recent Advances in Urology/Andrology. Edinburgh: Churchill Livingstone, 1981:291-323
4. Vierhapper H, Nowotny P, Waldhäusl W. Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab 1997;82:1492-6
5. Horton R, Shinsako J, Forsham PH. Testosterone production and metabolic clearance rates with volumes of distribution in normal men and women. Acta Endocrinologica 1965;48:446-58
6. Jockenhövel F. Anatomy and physiology of the testis. In: Male Hypogonadism. Bremen: Uni-Med Verlag AG, 2004:12-28
7. van der Molen HJ, de Bruijn HWA, Cooke BA, de Jong FH, Rommerts FFG. Regulation of the production of testicular steroids. In: James VHT, Serio M, Martini L, eds. The Endocrine Function of the Human Testis. Vol. I, New York: Academic Press, 1973:459-91
8. Yanaihara T, Troen P. Studies of the human testis. I. Biosynthetic pathways for androgen formation in human testicular tissue in vitro. J Clin Endocrinol Metab 1972;34:783-92
9. Wilson JD. Metabolism of testicular androgens. In: Greep RO, Astwood EB, eds. Handbook of Physiology, Section 7, Vol. 5. Washington, DC: American Physiological Society, 1975:491-508
10. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Recent Progr Horm Res 1953;8:379-418
11. Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R. Male development of chromosom-ally female mice transgenic for Sry. Nature 1991;351:117-21
12. Jost A. A new look at the mechanisms controlling sex differentiation in mammals. Johns Hopkins Med J 1972;130:38-53
13. Donahoe PK, Budzik GP, Trelstad R, et al. Müllerian-inhibiting substance: an update. Recent Progr Horm Res 1982;38:279-330
14. Wilson JD, Griffin JE, George FW, Leshin M. The role of gonadal steroids in sexual differentiation. Recent Progr Horm Res 1981;37:1-39
15. Wennink JMB, Delemarre van de Waal HA, Schoemaker R, et al. Luteinizing hormone and follicle stimulating hormone secretion in boys through puberty measured using highly sensitive immuno-radiometric assays. Clin Endocrinol (Oxf) 1989;31:551-64
16. Resko JA, Eik-Nes KA. Diurnal testosterone levels in peripheral plasma of human male subjects. J Clin Endocrinol Metab 1966;26:573-6
17. Plant TM. Hypothalamic control of the pituitary-gonadal axis in higher primates: key advances over the last two decades. J Neuroendocrinol 2008;20:719-26
18. Belchetz PE. Endocrinological problems in children and adolescents. In: Belchetz P, Hammond P, eds. Mosby's Color Atlas and Text of Diabetes and Endocrinology. Edinburgh: Mosby, 2003:219-30
19. Marshall WA, Tanner JM. Variation in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-24
20. Belchetz PE. Reproductive endocrinology. In: Belchetz P, Hammond P, eds. Mosby's Color Atlas and Text of Diabetes and Endocrinology. Edinburgh: Mosby, 2003:297-327
21. Hibberts NA, Howell AE, Randall VA. Balding hair follicles dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalps. J Endocrinol 1998;156:59-65
22. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-300
23. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003;26:76-83 (Pubitemid 36408236)
24. Tuck SP, Francis RM. Testosterone, bone and osteoporosis. Front Horm Res 2009;37:123-32
25. Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? QJMed 2003;96:521-9
26. Sharpe RM. Intratesticular control of spermatogenesis. Clin Endocrinol (Oxf) 1990;33:787-807
27. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isoenzymes and androgen action in the prostate. Ann NY Acad Sci 2009;1155:43-56
28. Rubinow DR, Schmidt PJ. Androgens, brain and behaviour. Am J Psychiatry 1996;153:974-84
29. Sakamoto H, Takanami K, Zuloaga DG, et al. Androgen regulates the sexually dimorphic gastrin-releasing peptide system in the lumbar spinal cord that mediates male sexual function. Endocrinology 2009;150:3672-9
30. Achermann JC, Hughes IA. Disorders of sex development. In: Kronenberg HM, Melmed S, Polonsky KS, Reed Larsen P, eds. Williams Textbook of Endocrinology. 11th edn. Philadelphia: Saunders, 2008:783-848
31. Ahmed SF, Cheng A, Dovey L, et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000;85:658-65
32. Ogata T, Matsuo N. The Y specific growth gene(s); how does it promote stature? J Med Genet 1997;34:323-15
33. Wilson JD, Harrod MJ, Goldstein JL, Hemsell DL, MacDonald PC. Familial incomplete male pseudohermaphroditism, type I. Evidence for androgen resistance and variable clinical manifestations in a family with the Reifenstein syndrome. N Engl J Med 1974;290:1097-103
34. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5 a-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213-5
35. Josso N, Belville C, di Clemente N, Picard J-Y. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum Reprod Update 2005;11:351-6
36. Prader A. Delayed adolescence. Clin Endocrinol Metab 1975;4:143-55
37. Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571-4
38. Melnik T, Soares BG, Nasselo AG. Psychosocial interventions for erectile dysfunction. Cochrane Database Syst Rev 2007;18:CD 004825
39. Ginsberg J. Flushes in men and women: circulatory and etiological aspects. In: Oddens BJ, Vermeulen A, eds. Androgens and the Aging Male. New York: Parthenon Publishing Group, 1996:129-46
40. Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med 2007;4:1241-6
41. Belchetz PE. The testis. In: Besser GM, Cudworth AG, eds. Clinical Endocrinology. An Illustrated Text. London: Gower Medical Publishing, 1987;10:1-18
42. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev 2008;29:441-64
43. Medvei VC. The History of Clinical Endocrinology. Lancaster: Parthenon Publishing Group, 1993
44. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;34:12-17
45. McLeod DG. Antiandrogenic drugs. Cancer 1993;71(3 Suppl):1046-9
46. Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974;59:665-78
47. Rosário PW, Barroso AL, Rezende LL, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid 2006;16:667-70
48. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. Lancet 2004;364:273-83
49. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and functional aspects of testicular descent and cryptorchidism. Endocr Rev 1997;18:259-80
50. Hanley HG, Harrison RG. The nature and surgical treatment of varicocele. Br J Surg 1962;50:64-7
51. Hayes PJ, Krishnan KR, Diver MJ, Hipkin LJ, Davis JC. Testicular endocrine function in paraplegic men. Clin Endocrinol (Oxf ) 1979;11:549-52
52. Singh R, Mostafid H, Hindley RG. Measles, mumps and rubella - the urologist's perspective. Int J Clin Pract 2006;60:335-9
53. Morley JE, Distiller LA, Sagel J, et al. Hormonal changes associated with testicular atrophy and gynaecomastia in patients with leprosy. Clin Endocrinol (Oxf) 1977;6:299-303
54. Söderbergh A, Wingvist O, Norheim I, et al. Adrenal antibodies and organ-specific autoimmunity in patients with Addison's disease. Clin Endocrinol (Oxf) 1996;45:453-60
55. Belchetz PE. Hypopituitarism. In: Belchetz PE, ed. Management of Pituitary Disease. London: Chapman and Hall Medical, 1984:103-15
56. Suliman SGI, Gurlek A, Byrne JV, et al. Nonsurgical cerebrospinal rhinorrhea in invasive macro-prolactinoma: incidence, radiological, and clinicopathological features. J Clin Endocrinol Metab 2007;92:3829-35
57. Franks S, Jacobs HS, Martin N, Nabarro JDN. Hyperprolactinaemia and impotence. Clin Endocrinol (Oxf) 1978;8:277-87
58. Ambler GR. Androgen therapy for delayed male puberty. Curr Opin Endocrinol Diabetes Obes 2009;16:232-9
59. Quinton R, Duke VM, Robertson A, et al. Idiopathic gonadotrophin deficiency: genetic questions answered through phenotypic characterization. Clin Endocrinol (Oxf) 2001;55:163-74
60. Hardelin JP, Dodé C. The complex genetics of Kallmann's syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. Sex Dev 2008;2:181-93
61. Quinton R, Hasan W, Grant W, et al. Gonadotropin-releasing hormone immunoreactivity in the nasal epithelia of adults with Kallmann's syndrome and isolated hypogonadotropic hypogonadism and in the early midtrimester human fetus. J Clin Endocrinol Metab 1997;82:309-14
62. Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term followup. Clin Endocrinol (Oxf) 2005;62:397-409
63. Plowman PN, Girard J, Irwin C, Sebag-Montefiore D. Craniopharyngiomas and other hypothalamic tumours. In: Grossman A, ed. Clinical Endocrinology, 2nd edn. Oxford: Blackwell Science, 1998:225-41
64. Smith AA, Weng E, Handler M, Foreman NK. Intracranial germ cell tumors: a single institution experience and review of the literature. J Neurooncol 2004;68:153-9
65. Janmohamed S, Grossman AB, Metcalfe K, et al. Suprasellar germ cell tumours: specific problems and the evolution of optimal management with a combined chemotherapy regimen. Clin Endocrinol (Oxf) 2002;57:487-500
66. Behan LA, Phillips J, Thompson CJ, Agha A. Neuroendocrine disorders after traumatic brain injury. J Neurol Neurosurg Psychiatry 2008;79:753-9
67. Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. QJMed 1989;262:145-60
68. Belchetz PE. Hypothalamo-pituitary disorders. In: Belchetz P, Hammond P, eds. Mosby's Color Atlas and Text of Diabetes and Endocrinology. Edinburgh: Mosby, 2003:177-217
69. Bannister P, Oakes J, Sheridan P, Losowsky M. Sex hormone changes in chronic liver disease: a matched study of alcoholic versus non-alcoholic liver disease. QJMed 1987;63:305-13
70. Anderson DC. Sex-hormone binding globulin. Clin Endocrinol (Oxf) 1974;3:69-96
71. Cundy T, Bomford A, Butler J, Wheeler M, Williams R. Hypogonadism and sexual dysfunction in hemochromatosis: the effects of cirrhosis and diabetes. J Clin Endocrinol Metab 1989;69:110-16
72. Bergeron C, Kovacs K. Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am J Pathol 1978;93:295-309
73. Wonke B, de Sanctis V. Endocrine manifestations in haemoglobinopathies. In: Grossman A, ed. Clinical Endocrinology. 2nd edn. Oxford: Blackwell Science, 1998:1087-95
74. Handelsman DJ. Hypothalamic-pituitary-gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev 1985;6:151-82
75. Toorians AW, Janssen E, Laan E, et al. Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response. Nephrol Dial Transplant 1997;12:2654-63
76. Gómez F, de la Cueva R, Wauters J-P, Lemarchand-Béraud T. Endocrine abnormalities in patients undergoing long-term hemodialysis: the role of prolactin. Am J Med 1980;68:522-30
77. Massry SG, Goldstein DA, Procci WR, Kletzky OA. Impotence in patients with uremia: a possible role for parathyroid hormone. Nephron 1977;19:305-10
78. Jamieson F, Chalmers J, Duncan C, Prescott RJ, Campbell IW. Erectile dysfunction in type 1 diabetic males. Br J Diabetes Vasc Dis 2008;8:232-4
79. Kapoor D, Goodwin E, Channer KS. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906
80. Stellato R, Feldman H, Hamdy O, Horton ES, McKinlay JB. Teatosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men. Diabetes Care 2000;23:490-4
81. Giagulli VA, Kaufman JM, Vermeulen A. pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994;79:997-1000
82. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androlol 1989;10:365-71
83. Jockenhövel F. Causes and differential diagnosis of hypogonadism. In: Male Hypogonadism. Bremen: Uni-Med Verlag AG, 2004:32-77
84. Cailleux-Bounacer A, Reznik Y, Cauliez B, et al. Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant LH in normal men. Eur J Endocrinol 2008;159:171-8
85. Antonini A, Poewe W. Fibrotic heart valve reactions to dopamineagonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9
86. Kars M, Pereira AM, Bax JJ, Rouijn JA. Cabergoline and cardiac disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 2008;159:363-7
87. Diver MJ. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem 2006;43:3-12
88. Wheeler MJ, Barnes SC. Measurement of testosterone in the diagnosis of hypogonadism in the ageing male. Clin Endocrinol (Oxf) 2008;69:515-25
89. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92:405-13
90. Middle J, UK NEQAS for steroid hormones 2008 annual review - participants version, personal communication
91. Cawood ML, Field HP, Ford CG, et al. Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry: validation of a method for routine clinical practice. Clin Chem 2005;51:1472-9
92. Manni A, Pardridge WM, Cefalu W, et al. Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 1985;61:705-10
93. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72
94. McCann DS, Kirkish LS. Evaluation of free testosterone in serum. J Clin Immunoassay 1985;8:234-6
95. Van Uytfanghe K, Stöckl D, Kaufman JM, et al. Evaluation of a candidate reference measurement procedure for serum free testosterone based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Chem 2004;50:2101-10
96. Martinez Jabaloyas JM, Queipo Zaragozá A, Gil Salom M, Chuan Nuez P. Evaluation of an immuno-assay kit to measure free testosterone. Actas Urol Esp 2006;30:598-601
97. Fritz FS, McKean AJ, Nelson JC, Wilcox RB. Analog-based free testosterone test results linked to to total testosterone concentrations, not free testosterone concentrations. Clin Chem 2008;54:512-16
98. Södergård R, Backström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10
99. Nanjee NN, Wheeler MJ. Plasma free testosterone - is an index sufficient? Ann Clin Biochem 1985;22:387-90
100. Morris PD, Malkin CJ, Channer KS, Hugh Jones T. A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol 2004;151:241-9
101. Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005;152:471-8
102. Kapoor P, Luttrell BM, Williams D. The free androgen index is not valid for adult males. J Steroid Biochem Mol Biol 1993;45:325-6
103. Vanbillemont G, Bogaert V, de Bacquert D, et al. Polymorphisms of the SHBG gene contribute to the interindividual variation of sex hormone blood levels in young, middle-aged and elderly men. Clin Endocrinol (Oxf) 2009;70:303-10
104. Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 2007;92:3604-10
105. Vermeulen A. Androgens in the aging male. J Clin Endocrinol Metab 1991;73:221-4
106. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724-31
107. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98
108. Lapauw B, Goemaere S, Zmierczak H, et al. The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes. Eur J Endocrinol 2008;159:459-68
109. Vermeulen A. Androgen replacement therapy in the aging male - a critical evaluation. J Clin Endocrinol Metab 2001;86:2380-90
110. Giannoulis MG, Sonksen PH, Umbley M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 2006;91:477-84
111. Mohr BA, Bhasin S, Link CL, O'Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts male aging study. Eur J Endocrinol 2006;155:443-52
112. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76
113. Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone in American men. J Clin Endocrinol Metab 2007;92:196-202
114. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts male ageing study. Clin Endocrinol (Oxf) 2005;62:64-73
115. Snyder PJ. Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med 2004;350:440-2
116. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-7
117. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92
118. Hoffman MA, de Wolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7
119. English KM, Steeds RP, Jones RH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-11
120. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings 2007;82:29-39
121. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-14
122. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res. 2009;21:1-8
123. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl 2009;32:1-10
124. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. J Androl 2009;30:1-9
125. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. EurUrol 2009;55:121-30
126. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Aging Male 2009;12:5-12
127. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154:502-21
128. Benveniste O, Simon A, Herson S. Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active retroviral therapy: four cases and a review of the literature. Clin Infect Dis 2001;33:891-3
129. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990;71:216-22
130. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 1999;50:629-35
131. Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol (Oxf) 1999;50:57-62
132. Franchimont P, Kicovic PM, Mattei A, Roulier R. Effects of oral testosterone undecanoate in hypogonadal male patients. Clin Endocrinol (Oxf) 1978;9:313-20
133. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-98
134. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-34
135. Dobs AS, Matsumoto AM, Wang C, Kipnes MS. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone-deficient men. Curr Med Res Opin 2004;20:729-38